Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics ADRs to Trade in US

NEW YORK (GenomeWeb News) – Epigenomics today said that it has established a Level 1 American Depositary Receipt program enabling the firm to trade publicly in the US.

The Berlin, Germany-based molecular diagnostics firm said that its ADRs are US dollar-negotiable certificates that represent ordinary shares of the company at a ratio of five ordinary shares to one Epigenomics ADR.

The ADRs are expected to begin trading today on the US OTC market under the ticker symbol 'EPGNY.' The firm's ordinary shares trade on the Frankfurt Prime Standard under the ticker symbol 'ECX.'

BNY Mellon is the depositary bank for the ADR program.

"We established the ADR program as a service to offer those investors an easy way to buy our shares and to consequently broaden the shareholder base in our core market," Thomas Taapken, CEO and CFO of Epigenomics, said in a statement.

The firm is awaiting a US Food and Drug Administration decision on the premarket approval application for its colorectal cancer test that it filed late last year. The Epi proColon test is based on the Septin9 protein and has been available as a CE-marked test kit in Europe and the Middle East since 2009. In 2011, Epigenomics launched an improved version, the Epi proColon 2.0 CE.

The FDA granted the firm's PMA application priority review status earlier this year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.